poly(lactide)-tocopheryl polyethylene glycol succinate

07/01/2015 - "The study describes the development of polylactide-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS)-based nanosystem as a carrier of crizotinib (CZT) to achieve superior anticancer efficacy in lung cancer therapy. "
02/01/2016 - "The aim of this work was to develop targeted polymeric micelles of poly-lactic acid-D-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS), which are assembled along with D-alpha-tocopheryl polyethylene glycol 1000 succinate-transferrin conjugate (TPGS-Tf), and loaded docetaxel (DTX) as a model drug for enhanced treatment of lung cancer in comparison to non-targeted polymeric micelles and DTX injection (Docel™). "

01/01/2018 - "Further, greater apoptosis, autophagy and ROS generation was induced by Gal-pD-PLA-TPGS/NPs in gastric cancer cells. "
01/01/2018 - "Gal-pD-PLA-TPGS/NPs more significantly reduced the gastric cancer cell viability. "
01/01/2018 - "Here, we found that BBL-loaded Gal-pD-PLA-TPGS/NPs showed the highest cellular uptake efficacy in gastric cancer cells. "
01/01/2018 - "Together, the findings indicated that BBL-loaded Gal-pD-PLA-TPGS/NPs could be targeted to gastric cancer cells to suppress tumor progression without toxicity."
01/01/2018 - "Additionally, compared to the other two NPs, Gal-pD-PLA-TPGS/NPs most markedly decreased ATP levels in gastric cancer cells. "

01/01/2018 - "Moreover, Gal-pD-PLA-TPGS/NPs exhibited the most anti-tumor effects, as evidenced by the lowest tumor volume and tumor weight. "
01/01/2018 - "In vivo, Gal-pD-PLA-TPGS/NPs were specifically targeted to tumor site. "
03/01/2014 - "The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles."
04/01/2011 - "The Xenograft model was also conducted for biodistribution of the QDs and IOs-loaded PLA-TPGS NPs among the various organs, which showed greatly enhanced tumor imaging due to the passively targeting effects of the NPs to the tumor. "
08/01/2008 - "The PLA-TPGS NP formulation can realize a way of controlled and sustained drug release for more than 10 days, which relieves one of the two major concerns on cancer nanotechnology, i.e. "

04/01/2011 - "The cellular uptake and the cytotoxicity of the PLA-TPGS NPs formulation of QDs and IOs were investigated in vitro with MCF-7 breast cancer cells, which were conducted in close comparison with the free QDs and IOs at the same agent dose. "
10/17/2013 - "In conclusion, such nanoparticles of star-shaped cholic acid-core PLA-TPGS block copolymer could be considered as a potentially promising and effective strategy for breast cancer treatment. "
10/11/2010 - "We first found that the activity of P-glycoprotein in drug-resistant breast cancer MCF-7/ADR cells was decreased after incubation with PLA-TPGS nanoparticles. "
10/17/2013 - "Paclitaxel-loaded nanoparticles of star-shaped cholic acid-core PLA-TPGS copolymer for breast cancer treatment."
02/01/2009 - "Additionally, our findings indicated that under same conditions, cytotoxicity of QDs formulated in the PLA-TPGS/TPGS-COOH NPs is lower for normal cells such as NIH 3T3 cells than that for breast cancer such as MCF-7 breast cancer cells due to folate targeting effect. "

09/01/2014 - "In summary, the star-like copolymer M-PLA-TPGS could be used as a potential and promising molecular biomaterial in developing novel nanoformulation for prostate cancer treatment."
09/01/2014 - "The purpose of this research was to develop novel nanoparticles (NPs) of star-like copolymer mannitol-functionalized poly(lactide)-vitamin E TPGS (M-PLA-TPGS) for paclitaxel delivery for prostate cancer treatment, and evaluate their therapeutic effects in prostate cancer cell line and animal model in comparison with the linear PLGA NPs and poly(lactide)-vitamin E TPGS (PLA-TPGS) NPs. "